Description
Latin name
Mycophenolate-Teva
Form
release Capsules
Packing
100 pcs.
Pharmacological action
Mycophenolate-Teva is an immunosuppressive drug morpholinoethyl ester of mycophenolic acid produced by Penicillium stoloniferum. It disrupts the synthesis of guanosine nucleotides, inhibiting inosine monophosphate dehydrogenase. It inhibits the proliferation of T- and B-lymphocytes, as well as the production of antibodies.
Indications
Prevention of acute organ rejection and refractory treatment in patients with refractory treatment.
Prevention of acute organ rejection and to improve transplant survival and patient survival after allogeneic heart transplantation.
Prevention of acute organ rejection in patients after allogeneic liver transplantation.
Contraindications
Hypersensitivity to mycophenolate mofetil.
Special instructions
Concomitant use with azathioprine is not recommended.
During treatment, regular monitoring of the blood condition is necessary. If the number of neutrophils is reduced to 1300 / Ñl, the dose of mycophenolate mofetil should be reduced or canceled.
Patients taking mycophenolate mofetil have an increased risk of lymphomas and other malignant tumors, in particular, skin cancer.
Composition
1 capsule contains benzalkonium chloride 18.9 mg
excipients: hydroxypropyl cellulose, silica colloidal dioxide, dimethicone 1000, 7-glyceryl cocoate polyoxyethylene glycol, macrogol 400, gelatin, glycerolfr34 1 capsule contains mycophenolate mofetil 250 mg
Dosage and administration
Used as part of combination therapy with cyclosporine and corticosteroids. To prevent the transplant rejection reaction, the first dose of mycophenolate mofetil is taken during the first 3 days after surgery. When administered, the recommended dose is 2 g / day, frequency of administration – 2 times / day.
For the treatment of rejection reactions – 3 g / day.
Side effects
From the hematopoietic system: leukopenia, thrombocytopenia, anemia.
From the urinary system: renal tubular necrosis, hematuria, albuminuria, dysuric phenomena, hyperuricemia.
From the cardiovascular system: arterial hypertension or hypotension, arrhythmias, coronary circulation disorders.
From the side of metabolism: hyper- or hypokalemia, hypophosphatemia, hyper- or hypocalcemia, hypervolemia, acidosis.
From the digestive system: gingivitis, gum hyperplasia, ulcerative stomatitis, nausea, vomiting, abdominal pain, constipation or diarrhea, esophagitis, gastritis, gastroenteritis, proctitis, hepatitis.
From the side of the central nervous system and peripheral nervous system: dizziness, tremors, sleep disturbances, anxiety, depression, drowsiness, paresthesia, conjunctivitis, amblyopia, cataracts.
From the endocrine system: hyperglycemia up to the development of diabetes mellitus, hypercholesterolemia, hypoproteinemia, weight gain, dysfunction of the parathyroid glands.
From the musculoskeletal system: myalgia, arthralgia, leg muscle cramps.
From the respiratory system: cough, shortness of breath, pharyngitis, sinusitis, bronchospasm.
Dermatological reactions: hirsutism, alopecia, pruritus, acne, ulceration of the skin, malignant neoplasms of the skin.
In connection with the immunosuppressive effect, it is possible to develop infectious lesions of various organs, including infections of the lower urinary tract, candidiasis of the gastrointestinal mucosa, herpetic and cytomegalovirus infection, aspergillosis.
Storage conditions
At a temperature not exceeding 30 ° C.
Expiration
2 years.
terms of sale from
pharmacies Prescription
dosage form
capsule
Teva Pharmaceutical Enterprise Co., Ltd., Israel
